Ashwagandha

With peptides

Ashwagandha is discussed alongside the growth-hormone-axis peptide cluster. CJC-1295 (a GHRH analog) and ipamorelin (a ghrelin mimetic / selective GH secretagogue) are reported to directly stimulate pituitary GH release. Sermorelin is a third GHRH-axis option. Ashwagandha is discussed as operating at complementary layers: reported cortisol reduction (chronically elevated cortisol is reported to suppress endogenous GH pulsatility) plus reported sleep-quality improvement (most nightly GH release occurs during slow-wave sleep). No negative interaction is documented in the sources reviewed for this page.

With supplements

1. Rhodiola rosea — a complementary adaptogen profile; rhodiola is reported as mildly stimulating (typically morning use) while ashwagandha is reported as calming (typically evening use). See the Ashwagandha vs Rhodiola Rosea comparison.
2. ZMA — zinc, magnesium, and B6 for sleep architecture and mineral repletion, a complementary mechanism.
3. L-theanine — reported alpha-wave calm-focus and GABAergic enhancement.
4. Magnesium glycinate — GABAergic and neuromuscular relaxation, a complementary calming and recovery mechanism.
5. GABA — direct GABAergic supplementation, mechanistically overlapping with ashwagandha's GABA-mimetic activity.
6. Fenugreek — a testosterone-axis adjunct via a different reported mechanism (aromatase and 5-AR inhibition).
7. Phosphatidylserine — an acute cortisol-blunting effect around exercise, discussed alongside ashwagandha's chronic cortisol modulation.

With lifestyle factors

1. Resistance training. The reported strength-training-adjunct effect (Wankhede et al. 2015, Ziegenfuss et al. 2018) is paired with a consistent training stimulus in those trials.
2. Consistent sleep schedule. Ashwagandha's reported sleep-quality support is discussed alongside the GH-axis and cortisol-recovery contexts it operates within.
3. Evening dosing with dinner. Aligns with the cortisol-reduction and slow-wave-sleep mechanisms discussed above.
4. Thyroid panel before starting. Relevant for people with thyroid concerns or a family history, given ashwagandha's reported effect on thyroid hormone levels.
5. Chronic stress contexts. Burnout, high-volume training, and sleep-deprived periods are the contexts in which the trial effects are reported as largest.
6. Alcohol or sedatives. Additive sedation is theoretically possible at high doses via the GABA-mimetic mechanism.

Common (mostly transient)

1. Mild GI discomfort — reported occasionally, generally at higher doses or on an empty stomach.
2. Drowsiness — the intended effect for evening dosing; reported as undesirable if dosed earlier in the day for sensitive users.
3. Nausea or loose stools — reported uncommonly, dose-related.
4. No serious adverse events are documented at standard supplemental doses across the RCT base cited above.

Less common (watch-list)

1. Thyroid hormone elevation. Sharma et al. 2018 reports T4 and T3 increases — beneficial in subclinical hypothyroidism but a consideration for thyroid-medicated or hyperthyroid users. TSH/free T4 monitoring every 6–8 weeks is standard guidance if combined with thyroid medication.
2. Rare liver injury at very high doses. Case reports published 2020–2023 flag occasional hepatotoxicity at chronic doses of 1,500+ mg/day, well above the 300–600 mg/day range used in the RCTs cited above.
3. Pregnancy contraindication. Traditional Ayurvedic use includes as a uterine stimulant; avoidance during pregnancy is standard guidance.
4. Hyperthyroidism / Graves' disease — the reported thyroid-hormone-raising effect could theoretically worsen thyrotoxicosis.
5. Autoimmune conditions (Hashimoto's, lupus, MS) — theoretical immune-modulation concerns are discussed in the literature; specialist coordination is standard guidance.
6. Solanaceae (nightshade family) allergies — ashwagandha is a member of this family, with possible cross-reactivity.

Drug and supplement interactions

1. Thyroid medication (levothyroxine, T3). Ashwagandha's reported thyroid-hormone-raising effect may require a thyroid medication dose adjustment; clinician coordination and TSH/free T4 monitoring every 6–8 weeks is standard guidance.
2. Sedatives (benzodiazepines, Z-drugs). Additive sedation is possible via the GABA-mimetic mechanism.
3. Antihypertensive medications. A mild additive BP-lowering effect is reported; BP monitoring during titration is standard guidance.
4. Immunosuppressants. A theoretical immune-modulation interaction is discussed; specialist coordination is standard guidance for organ-transplant or autoimmune contexts.
5. Diabetes medications — a mild glucose-lowering effect is reported; glucose monitoring is standard guidance if combined with insulin or sulfonylureas.
6. Pregnancy and breastfeeding — avoidance is standard guidance, per the traditional uterine-stimulant use noted above.

How do KSM-66, Sensoril, and unstandardized ashwagandha extracts compare?

KSM-66 (a root-only extract standardized to 5% withanolides) is the most-studied branded form and is the extract used in most of the positive trials cited on this page (Wankhede et al. 2015, Salve et al. 2019). Sensoril (a root-plus-leaf extract standardized to 10% withanolides) is reported in some trials to produce a stronger cortisol-reduction effect, reflecting a different bioactive profile (Ziegenfuss et al. 2018). Products listing 'ashwagandha extract' without disclosing a withanolide percentage or branded standardization are reported to vary considerably in active-compound content and are not the form the trial evidence was generated on.

Does the evidence support a testosterone-raising effect for ashwagandha?

The trial evidence reports a real but context-dependent effect. Wankhede et al. 2015's KSM-66 trial in resistance-trained men reports testosterone increased 96.2 ng/dL versus 18.0 ng/dL with placebo over 8 weeks. Lopresti et al. 2019, in stressed adults, reports testosterone and DHEA-S increases alongside cortisol reduction. The mechanism discussed in the literature is that chronically elevated cortisol suppresses testosterone production, and ashwagandha's reported cortisol-lowering effect relieves that suppression — meaning the effect is described as most relevant in stressed, training-loaded, sleep-disrupted, or hypogonadal populations where cortisol elevation is a limiting factor, with a smaller reported effect in young, healthy, low-stress men with normal cortisol.

What dose of ashwagandha appears in the cited trials?

Trials commonly used 300–600 mg/day of standardized extract. Wankhede et al. 2015 used 300 mg KSM-66 twice daily; Chandrasekhar et al. 2012 used 300 mg twice daily for stress reduction; Lopresti et al. 2019 used 240 mg/day of a Shoden extract; Salve et al. 2019's sleep trial used 600 mg/day. Doses above roughly 1,000 mg/day are not reported to add clear additional benefit in the trials reviewed and are associated with more reported GI effects.

What does the evidence say about ashwagandha and sleep?

Salve et al. 2019's 60-day trial of 600 mg/day in adults with insomnia reports significant sleep-quality improvement on the Pittsburgh Sleep Quality Index versus placebo. The proposed mechanism combines a GABA-mimetic effect (withanolides are reported to bind GABA receptors) with reduced cortisol-mediated arousal, since chronic cortisol elevation is reported to impair sleep architecture. Effect is reported to build over 2–4 weeks of consistent evening dosing rather than acting acutely like melatonin.

Does ashwagandha stack with CJC-1295 or ipamorelin?

The mechanisms are reported as complementary rather than overlapping. CJC-1295 (a GHRH analog) and ipamorelin (a ghrelin mimetic / selective GH secretagogue) directly stimulate pituitary GH release. Sermorelin is a third GHRH-axis option. Ashwagandha is discussed as operating at a different layer: reported cortisol reduction (chronically elevated cortisol is reported to suppress GH pulsatility) plus reported sleep-quality improvement (the majority of nightly GH release occurs during slow-wave sleep). No negative interaction is documented in the sources reviewed for this page.

What thyroid considerations does the evidence report for ashwagandha?

The literature reports two contexts requiring attention. In subclinical hypothyroidism, Sharma et al. 2018's 8-week trial reports ashwagandha (600 mg/day) significantly improved TSH, T3, and T4 levels compared to placebo — a finding that could be beneficial in this specific population but is reported as potentially relevant for anyone already on thyroid medication, since combined thyroid-hormone-raising effects could require dose adjustment. In hyperthyroidism or Graves' disease, the reported thyroid-hormone-raising effect is flagged as a theoretical concern for worsening thyrotoxicosis. TSH and free T4/T3 monitoring is standard guidance when combining with thyroid medication.

Does dosing time of day matter for ashwagandha?

Evening dosing is the pattern used in the sleep-focused trial (Salve et al. 2019, 600 mg evening), leveraging the reported cortisol-reduction and sleep-architecture mechanisms. The testosterone/strength trial (Wankhede et al. 2015) used a split AM/PM protocol (300 mg twice daily). Morning-only dosing is reported by some users to avoid next-day drowsiness, though this pattern was not specifically the protocol tested in the cited sleep trial.

What does the literature report about ashwagandha and liver safety?

Case reports published in the medical literature between 2020 and 2023 have flagged rare liver injury associated with very high chronic doses (1,500+ mg/day). At the doses used in the RCTs cited on this page (300–600 mg/day), no consistent hepatotoxicity signal is reported. The case-report literature has drawn attention to root-plus-leaf preparations (such as Sensoril) more than root-only preparations (such as KSM-66) as a point worth noting, though a direct causal comparison between forms has not been established in controlled trials reviewed for this page.